Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Bayer Yakuhin Sales Up 16.5% Driven by New Product Growth
April 9, 2014
- Oncolys, BMS End Collaboration for Anti-HIV Drug Development
April 9, 2014
- Santen Licenses Tafluprost Marketing Rights in US to Oak Pharmaceuticals
April 9, 2014
- Sun Deal Not Meant to Sever Ties with Ranbaxy: Daiichi Sankyo Pres.
April 8, 2014
- Daiichi Sankyo’s Governance over Ranbaxy Shaky to the End
April 8, 2014
- Novartis Gives Update on SIGN Probe, Personnel Change to JPMA
April 8, 2014
- Why Did Sanofi Decide to Begin Independent Marketing? Future Relationship with Nichi-Iko Remains in Doubt
April 8, 2014
- Japan Generic Market Put at 780 Billion Yen in 2016, Biosimilars 26.4 Billion Yen: Fuji Keizai
April 8, 2014
- India’s Sun Pharma to Acquire Ranbaxy via Equity Swap Deal, Taking Ranbaxy Off Daiichi Sankyo Scorecard
April 7, 2014
- GSK’s Japan Unit Mulls Recalling Paxil after FDA Warning
April 7, 2014
- Astellas Seeks European Approval of XTANDI for Chemotherapy-Naïve Prostate Cancer Patients
April 7, 2014
- Latuda Approved for Bipolar Depression in Canada: DSP
April 7, 2014
- Gilead’s Novel Hepatitis C Drug Beats Primary Endpoint in PIII, Filing Slated for Mid-Year
April 7, 2014
- Novartis Replaces Japan Unit Head amid SIGN Trial Probe
April 4, 2014
- Sanofi Japan Sales Down 3.9% as Generics Take Toll
April 4, 2014
- Daiichi Sankyo Initiates Multinational ENSURE-AF Study of Edoxaban in the US, Europe
April 4, 2014
- Sawai Stands Out with Operating Profit Rate of 25% in 3rd Quarter, Moving into Top Level of the Industry
April 4, 2014
- Sales Rep Wrote Out Side Effect Grades for Doctors in SIGN Trial: Panel
April 3, 2014
- Independent Panel Finds Transgression of Fair Competition Code, Cover-Up over SIGN Trial
April 3, 2014
- COO Weber Wants Takeda to Be Global Leader
April 3, 2014
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…